After the Biotech Bubble Bursts

After a decade where deal volumes expanded, biotech valuations exploded, and venture capital flooded the biopharma market like never before, the public biotech bubble has burst. So, now what? Pharma will still seek external innovation, biotechs will still need investment, but what will the post-bubble landscape look like and how can innovative science successfully emerge?

Analyst and journalist Melanie Senior joins long-time biopharma investor Stephan Christgau, Founding Partner at EIR Ventures, Dr. Steven Cohen, Executive Director at Daiichi Sankyo, and Dylan van Haaften, Managing Director at Bryan, Garnier & Co. to discuss what a bursting biotech bubble means for dealmaking, innovation, and the industry. They discussed what to expect in the investment market in the year ahead, where investments will continue to grow and where they may dry up, and how biotechs and pharma companies can position themselves for success in a post-bubble market.